Sun Pharmaceutical Industries Limited — PPTs, 27-04-2026: Investor Presentation

Sun Pharma is set to transform into a global pharma leader. The company recently announced the acquisition of Organon & Co.

**Business Performance:** Sun Pharma's FY25 revenue was $6.2 billion. This acquisition is projected to nearly double combined revenue to ~$12.4 billion and EBITDA to ~$3.7 billion. The merged entity will see innovative medicines contribute 27% and established brands 51% of revenue, with Organon bringing leadership in Women's Health and biosimilars (#7 globally).

**Growth Strategy:** Sun plans to leverage its lean operations and branded generics expertise to revitalize Organon's portfolio, creating a powerful global commercial platform across 150+ markets. This will drive product cross-pollination and establish Sun as a preferred licensing partner, with over $350 million in synergies expected.

**Outlook:** Management anticipates accelerating global transformation, expanding market presence especially in Europe, China, and Korea. Strong combined cash flows will fund future growth and strategic priorities, unlocking significant value for the company.